Gertrude Biomedical develops small molecule inhibitors to target transcription factors driving cancer growth, focusing on SOX18. Their precision oncology approach aims to disrupt tumor angiogenesis and directly target cancer cells, offering a novel therapeutic modality for difficult-to-treat cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Many advanced cancers are currently untreatable due to limitations in targeting key cellular mechanisms. Specifically, transcription factors, which regulate gene expression, have historically been difficult to target with small molecule inhibitors, leaving significant therapeutic opportunities unexplored.
Solution
Gertrude Biomedical is developing novel small molecule inhibitors designed to target transcription factors that drive cancer growth and proliferation. The company's precision oncology approach focuses on inhibiting SOX18, a master regulator implicated in angiogenesis and cancer cell programs. By developing multi-modal therapeutics, Gertrude Biomedical aims to simultaneously disrupt the blood supply to tumors and directly target cancer cells expressing SOX18. This strategy addresses multiple hallmarks of cancer, offering a new therapeutic modality for patients with unmet needs.
Target Audience
The primary target audience includes oncologists, pharmaceutical companies, and researchers focused on developing novel therapeutics for difficult-to-treat cancers, particularly those involving SOX18-dependent pathways.
Features
- Development of small molecule inhibitors targeting transcription factors, specifically SOX18.
- Dual-action therapeutic strategy: inhibiting tumor angiogenesis and directly targeting SOX18-expressing cancer cells.
- Focus on regulating gene expression pathways critical for cancer cell proliferation, inflammation, and angiogenesis.
- Application of medicinal chemistry and drug development expertise to "drug the undruggable."
- Potential for multi-modal treatment addressing several cancer hallmarks simultaneously.